Nephrology
Stories
-
Roche posts Phase 3 results for obinutuzumab in childhood nephrotic syndrome
Hoffmann-La Roche posted results on October 14, 2026 for its INShore trial of obinutuzumab against mycophenolate mofetil. The record lists sustained complete remission at Week 52 in 95.5% of 44 participants on obinutuzumab and 73.2% of 41 on mycophenolate mofetil.